Spherix Global Insights

November 11, 2021

The Very Slow Roll of Biogen’s Aduhelm: Neurologists Weigh in on Patients, Practices and Payments Amid Ongoing Media Storm

From: Endpoints News

By: Beth Snyder Bulik

Endpoints News - Venrock


Five months after the approval of Biogen’s Aduhelm, the bad news just keeps piling up for the Alzheimer’s drug. The confirmation yesterday of a Biogen investigation into the death of trial participant is the latest setback, but it adds to a laundry list of ongoing woes including insurance reimbursement uncertainty, dismal initial sales, a label flipflop, FDA advisory committee members resigning and outspoken researchers and public officials who continue to question the drug’s approval

So what to do about Aduhelm’s image? Not much for the neurologists beyond their clinical practice and personal interactions, however Biogen could potentially tackle it. Spherix Global Insights recently offered suggestions based on its interviews with neurologists that might help uptake…(read more)